Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by noGnoG8on Mar 12, 2012 4:17pm
232 Views
Post# 19659052

Alzheimer’s

Alzheimer’s

Alzheimer’s Costs to Top $200 Billion a Year

New report paints grim picture.

VINAY SINGH

The Burrill Report

“Alzheimer’s disease affects 5.4 million Americans and one in eight people older than 65 are afflicted by the disease.”

Caring for people with Alzheimer’s or other related dementias will cost the United States an estimated $200 billion in 2012, according to a new report from the Alzheimer’s Association.

Currently, most of the cost burden is paid by Medicaid and Medicare. The report finds that average per-person Medicaid payments are 19 times higher for seniors with Alzheimer’s and other dementias. Medicare payments are three times higher.

“These numbers will only continue to soar in the coming years, given the projected rapidly escalating prevalence of Alzheimer’s disease as baby boomers age,” says the report, which suggests that the expense of caring for people with Alzheimer’s could reach $1 trillion by 2050 if nothing is actively done to curb the disease.

One in seven people with Alzheimer’s, or about 800,000 U.S. citizens, live alone and nearly half of those individuals have no appointed caregiver, further raising the hazards posed by dementia. These individuals are much more likely to go undiagnosed, fall, or even die compared to people with Alzheimer’s who don’t live alone.

Alzheimer’s disease affects 5.4 million Americans and one in eight people older than 65 are afflicted by the disease. It is currently the sixth leading cause of death and the only cause of death amongst the top 10 that lacks a means of being prevented, slowed, or cured all together.

“While lives affected and care costs soar, the cost of doing nothing is far greater than acting now,” says Harry Johns, president and CEO of the Alzheimer’s Association said. “Alzheimer’s is a tremendous cost-driver for families and for Medicare and Medicaid. This crisis simply cannot be allowed to reach its maximum scale because it will overwhelm an already overburdened system.”


Bullboard Posts